Rocket Pharmaceuticals, Inc. 已成功完成其罕见儿科疾病优先审评券的出售,交易总额为1.8亿美元。此举将为公司带来可观的非稀释性资金,用于推进其针对严重罕见疾病的基因治疗产品管线的研发。
Rocket Pharmaceuticals, Inc. 已成功完成其罕见儿科疾病优先审评券的出售,交易总额为1.8亿美元。此举将为公司带来可观的非稀释性资金,用于推进其针对严重罕见疾病的基因治疗产品管线的研发。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.